<DOC>
	<DOCNO>NCT02467413</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy BAC patient Alzheimer 's disease vascular dementia.The secondary objective study evaluate safety BAC patient Alzheimer 's disease vascular dementia .</brief_summary>
	<brief_title>BAC Patient With Alzheimer 's Disease Vascular Dementia</brief_title>
	<detailed_description>This study design randomize , double-blind , vehicle-controlled parallel trial evaluate efficacy safety BAC patient Alzheimer 's disease vascular dementia . Eligible patient randomly assign receive either one topical application BAC BAC match vehicle , topical application external nasal skin , scalp , neck , 30mL/day , 2 time daily . The treatment duration patient 12 week , consist 6 visit locate Screening , Baseline ( Week 0 ) , Weeks -2 , -4 , -8 , -12 . During treatment period , patient may continue receive routinely used medication treatment Alzheimer 's disease vascular dementia except prohibit protocol .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<criteria>A patient eligible study follow apply : 1 . With either gender age least 40 year old 2 . With diagnosis one follow disease i. Vascular dementia accord NINDSAIREN International Workshop criterion ii . Alzheimer 's disease accord NIAAA criterion iii . `` Mixed '' dementia ( possible Alzheimer 's disease cerebrovascular disease ) accord NIAAA criterion Note : 1 . NINDSAIREN : National Institute Neurological Disorders Stroke Association Internationale pour la Recherche et l'Enseignement en Neurosciences 2 . NIAAA : National Institute AgingAlzheimer 's Association 3 . With mildtomoderate dementia ( score MiniMental State Examination ( MMSE ) define 10 24 ) 4 . Able read , write , communicate , understand cognitive testing instruction 5 . Having responsible caregiver spend adequate time daily patient ; caregiver accompany patient clinic visit study supervise study dose requirement concomitant medication 6 . Signed , patient responsible caregiver , write informed consent form 1 . With largeartery stroke ( thrombotic stroke ) 2 . With radiological evidence brain disorder ( subdural hematoma , posttraumatic / postsurgery ) 3 . With dementia cause brain disease except Alzheimer 's disease vascular dementia ( e.g . Parkinson 's disease , demyelinate disease central nervous system , tumor , hydrocephalus , head injury , central nervous system infection include syphilis , acquire immune deficiency syndrome , etc . ) 4 . With clinical evidence pulmonary , hepatic , gastrointestinal , metabolic , endocrine life threaten disease judge investigator suitable enter study 5 . With clinically unstable hypertension , diabetes mellitus , cardiac disease last 3 month 6 . With history stroke hospitalize stroke previous 3 month 7 . With history alcohol drug abuse 8 . With one follow abnormal laboratory parameter : hemoglobin &lt; 10 mg/dL platelet &lt; 100*109/L ; creatinine total bilirubin 1.5 time upper limit value ; alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphate ( ALP ) , γglutamyl transferase ( γGT ) 2 time upper limit normal 9 . With depression , wellcontrolled medication . 10 . With uncontrolled illness judge investigator enter trial may detrimental patient 11 . With know suspected hypersensitivity ingredient study product vehicle 12 . Pregnant lactate premenopausal childbearing potential take reliable contraceptive method ( ) study period 13 . Enrollment investigational drug trial within 4 week enter study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Vascular Dementia</keyword>
</DOC>